A Study to Evaluate the Efficacy and Safety of AD-224
Recruiting
Phase 3
Interventional Study
Hypertension,Essential
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 252 (estimated)
- Sponsor
- Addpharma Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the efficacy and safety of AD-224
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Signed informed consent
* Patients with Essential Hypertension
* Other inclusions applied
Exclusion Criteria:
* Patient with Secondary Hypertension
* Other exclusions applied
Contacts